Three-year phase 1 follow-up data for mrna-based individualized immunotherapy candidate show persistence of immune response and delayed tumor recurrence in some patients with resected pancreatic cancer

Mainz, germany, april 7, 2024 -  biontech se (nasdaq: bntx, “biontech” or “the company”) today announced three-year follow-up data from a phase 1 trial with the mrna-based individualized neoantigen-specific immunotherapy (“inest”) candidate autogene cevumeran (also known as bnt122, ro7198457) in patients with resected pancreatic ductal adenocarcinoma (“pdac”). the data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated t cells. the persistence of t cels was associated with a longer median recurrence-free survival in cancer vaccine responders.
BNTX Ratings Summary
BNTX Quant Ranking